Regulus Therapeutics (RGLS) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Regulus Therapeutics (NASDAQ: RGLS):

• 5/18/2025 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 5/10/2025 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 5/1/2025 – Regulus Therapeutics had its “equal weight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $9.00 price target on the stock.
• 4/30/2025 – Regulus Therapeutics had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $7.00 price target on the stock.
• 4/30/2025 – Regulus Therapeutics was downgraded by analysts at Wells Fargo & Company from a “strong-buy” rating to a “hold” rating.
• 4/30/2025 – Regulus Therapeutics was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 4/30/2025 – Regulus Therapeutics had its “hold” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $11.00 price target on the stock, down previously from $28.00.
• 4/30/2025 – Regulus Therapeutics had its “hold” rating reaffirmed by analysts at Jones Trading. They now have a $7.00 price target on the stock, down previously from $8.00.
• 3/27/2025 – Regulus Therapeutics was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $6.00 price target on the stock, up previously from $3.00.

Regulus Therapeutics Trading Down 0.1%

Regulus Therapeutics stock traded down $0.01 during midday trading on Monday, hitting $7.87. The stock had a trading volume of 407,777 shares, compared to its average volume of 889,331. The firm’s fifty day moving average is $3.41 and its two-hundred day moving average is $2.10. The company has a market capitalization of $544.53 million, a PE ratio of -7.35 and a beta of 0.49. Regulus Therapeutics Inc. has a 52-week low of $0.83 and a 52-week high of $8.20.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.14. As a group, equities research analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RGLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Regulus Therapeutics by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,345 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 1,644 shares in the last quarter. PEAK6 LLC bought a new stake in shares of Regulus Therapeutics in the fourth quarter valued at about $95,000. Oppenheimer & Co. Inc. bought a new stake in shares of Regulus Therapeutics in the first quarter valued at about $96,000. Velan Capital Investment Management LP bought a new stake in shares of Regulus Therapeutics in the fourth quarter valued at about $111,000. Finally, AQR Capital Management LLC bought a new position in Regulus Therapeutics in the first quarter worth about $120,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.